Gujarat Themis Biosyn releases 2.55 million pledged shares held by Pharmaceutical Business Group

What Gujarat Themis Biosyn announced

On 16 July 2026, Gujarat Themis Biosyn Ltd (the "Target") received a disclosure from its promoter, Pharmaceutical Business Group (India) Limited (the "Promoter"), that a pledge on a portion of the Promoter’s shareholding had been released. The release pertains to 2,545,000 equity shares that were previously pledged.

The pledge release removes a 2.34% encumbrance on the Target’s total share capital.

The filing was made under Regulation 31(1) and 31(2) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 and was submitted to both BSE and NSE.

Details of the pledge release

• Promoter’s total holding: 51,240,000 shares, equivalent to 47.02% of Gujarat Themis Biosyn’s issued share capital.
• Pledged shares before release: 2,545,000 shares, representing 2.34% of the total share capital.
• Date of release: 8 July 2026.
• Nature of encumbrance: Pledge (no lien, non‑disposal undertaking, or other type).
• Post‑event encumbrance: Zero pledged shares remain after the release.
• Other minor encumbrances: Bajaj Finance Limited holds 5,000 shares (0.004% of total) but this is unrelated to the pledge release.

The promoter’s declaration follows the standard format prescribed by SEBI, listing the promoter’s shareholding, the amount already encumbered, and the change resulting from the release.

Key facts at a glance

Why this matters for investors

The removal of a pledge reduces the risk that the promoter’s shares could be forced to be sold to satisfy a creditor. For shareholders, a lower encumbrance level generally improves the perception of share‑holding stability and may positively affect the company’s governance profile. The promoter still retains a substantial equity stake (nearly half of the company), indicating continued confidence in the business. No new securities were issued, and there is no dilution impact on existing shareholders.

Conclusion

The filing confirms that Pharmaceutical Business Group has fully released the pledged 2.55 million shares on 8 July 2026, eliminating a 2.34% encumbrance on Gujarat Themis Biosyn Ltd. The promoter’s overall shareholding remains unchanged at 47.02% of the company. No further actions or approvals are pending under this disclosure.